After finishing graduate school, Saha joined the management consulting firm
McKinsey & Company in their Pharmaceuticals and Medical Products Practice in New York City. In 2005, he became the Director of the New Indications Discovery Unit at the Novartis Institutes for BioMedical Research based in Cambridge, Massachusetts. Between 2008 and 2015, Saha served as the President of BioMed Valley Discoveries Saha serves as a venture partner for the life sciences venture capital firm,
Atlas Venture and also served as the Chief Medical Officer for its portfolio company, Synlogic. In 2016, Saha was appointed as President and
CEO of Delinia, a biotech company focused on developing novel therapies for the treatment of cancer and autoimmune diseases such as
lupus,
inflammatory bowel disease,
rheumatoid arthritis and others. Saha has published in periodicals where he and his colleagues reported translational research and development discoveries in cancer research. He is also on the editorial boards of the
American Journal of Clinical Oncology,
Journal of Translational Medicine, and
Cancer Biology & Therapy. ==References==